A fundamental feature of central nervous system development is that neurons are generated before glia. In the embryonic spinal cord, for example, a group of neuroepithelial stem cells (NSCs) generates motor neurons (MNs), before switching abruptly to oligodendrocyte precursors (OLPs). We asked how transcription factor OLIG2 participates in this MN-OLP fate switch. We found that Serine 147 in the helix-loop-helix domain of OLIG2 was phosphorylated during MN production and dephosphorylated at the onset of OLP genesis. Mutating Serine 147 to Alanine (S147A) abolished MN production without preventing OLP production in transgenic mice, chicks, or cultured P19 cells. We conclude that S147 phosphorylation, possibly by protein kinase A, is required for MN but not OLP genesis and propose that dephosphorylation triggers the MN-OLP switch. Wild-type OLIG2 forms stable homodimers, whereas mutant (unphosphorylated) OLIG2 S147A prefers to form heterodimers with Neurogenin 2 or other bHLH partners, suggesting a molecular basis for the switch.
INTRODUCTION
All the neurons and glial cells of the mature central nervous system (CNS) are generated by neuroepithelial stem cells (NSCs) in the ventricular zone (VZ) that surrounds the lumen of the embryonic neural tube (forerunner of the spinal cord and brain). Cell diversification occurs in stages. First, a neurogenic prepattern is laid down in the plane of the VZ, under the action of graded morphogens released from organizing centers within or outside the neural tube. This leads to a mosaic of molecularly distinct progenitor domains, each of which goes on to generate a characteristic subset of neurons and glia. Superimposed on this spatial pattern is a temporal pattern of cell generation from some regions of the VZ. For example, in the developing cerebral cortex, different classes of projection neuron are generated in sequence (Shen et al., 2006) ; these settle in stereotypic positions to generate the layered structure of the cortex. Subsequently, cortical NSCs start to produce glial lineages (astrocytes and oligodendrocytes [OLs] ). This late neuron-glial switch is a general property of NSCs in all parts of the developing brain and spinal cord. In some areas of the VZ, NSCs switch from neuron to astrocyte production, whereas other regions generate oligodendrocyte precursors (OLPs), which migrate widely before differentiating into myelin-forming OLs (Rowitch, 2004; Richardson et al., 2006) . Less is known about the temporal control of cell fate than the spatial patterning that precedes it. We set out to study this temporal aspect of cell diversification, focusing on neuron-glial switching in the ventral spinal cord.
Spatial pattern in the ventral half of the developing spinal cord is established largely through the action of Sonic hedgehog (SHH) protein released from the notochord and floor plate at the ventral midline. SHH activates or inhibits different sets of transcription factors at different distances from the floor plate (different concentrations of SHH). Subsequently, cross-repressive interactions among the transcription factors expressed in adjacent regions of the VZ establish sharp boundaries of gene expression in the dorsal-ventral axis, establishing a set of ribbon-like NSC domains that run parallel to one another along the neuraxis. In the ventral half of the cord, these domains are known (from ventral to dorsal) as p3, pMN, p2, p1, and p0 (Jessell, 2000) . Six additional NSC domains (dP1-dP6, dorsal to ventral) are formed in the dorsal half of the spinal cord under the influence of BMPs and WNTs secreted from the roof plate (Helms and Johnson, 2003) . NSCs in the ventral pMN domain generate several different subtypes of motor neuron (MN) before switching abruptly to OLP production (reviewed by Richardson et al., 2000) . NSCs in the neighboring p3 and p2 domains generate interneurons followed by astrocytes .
The pMN domain contributes all of the MNs and $80% of the OLPs in the mouse spinal cord (Fogarty, 2006; Richardson et al., 2006) . The remaining OLPs are generated outside pMN in a SHH-independent manner (Cai et al., 2005; Fogarty et al., 2005; Vallstedt et al., 2005) . pMN is marked by transcription factor OLIG2 and its close relative OLIG1, which were originally identified in screens for OL-specific genes (Lu et al., 2000; Takebayashi et al., 2000; Zhou et al., 2000) . OLIG2 knockout results in loss of the pMN domain and consequently complete absence of spinal MNs Takebayashi et al., 2002; Zhou and Anderson, 2002; Park et al., 2002) . All spinal OL lineage cells are lost as well because OLIG2 is required for OLP development regardless of whether they are generated within or outside of pMN Takebayashi et al., 2002; Zhou and Anderson, 2002; Park et al., 2002) . In contrast, OLIG1 has a relatively mild impact on normal development J.P.d.F ., N. Kessaris, W.D.R., and H.L., unpublished data; but see Xin et al., 2005) . However, OLIG1 is believed to be crucial for OL regeneration in demyelinating diseases such as multiple sclerosis (Arnett et al., 2004) .
The OLIG gene products are members of a large family of helixloop-helix (HLH) transcription factors, which also includes proneural proteins Neurogenin1/2 (NGN1/2) and MASH1/ASCL1 as well as cell lineage regulators MYOD and NEUROD. OLIG2 interacts with different protein partners to regulate specific developmental processes. It can form heterodimers with NGN2 to control MN differentiation, and it can bind NKX2.2 to promote OLP generation and/or differentiation (Novitch et al., 2001; Zhou et al., 2001; Qi et al., 2001; Sun et al., 2003; Lee et al., 2005) . It can also complex with SOX10 or ZFP488 to regulate OLP differentiation and enhance myelin gene expression Wissmuller et al., 2006; Li et al., 2007) .
Given the central role of OLIG2 in both MN and OL development, we were keen to discover how this one transcription factor can specify two quite different cell types and especially how it participates in the MN-OLP temporal fate switch. We present evidence that OLIG2 controls the switch by reversible phosphorylation on Serine 147 (S147), a predicted protein kinase A (PKA) target; phosphorylation at this site is required for patterning of the ventral neuroepithelium and MN specification, whereas dephosphorylation favors OLP specification. S147 phosphorylation also causes OLIG2 to switch its preferred dimerization partner from OLIG2 (or OLIG1) to NGN2. We propose that this regulated exchange of cofactors is required for and triggers the MN-OLP fate switch.
RESULTS

OLIG2 Is Reversibly Phosphorylated on Serine 147
OLIG2 is rich in serine and threonine residues (50 serines and 14 threonines out of a total of 323 amino acids; see Table S1 available online), suggesting that it might possess multiple serine/ threonine phosphorylation sites. To test this, we transfected a Myc epitope-tagged OLIG2 expression vector into Cos-7 cells, (G and H) OLIG2-S147 was phosphorylated in vivo. Mouse spinal cord homogenates from different developmental stages were analyzed by IP with goat anti-OLIG2, followed by WB with (G) rabbit anti-OLIG2 or (H) rabbit anti-OLIG2 ph-S147 . See also Figure S1 and Table S1. labeled the cells with [ 33 P]phosphate, and analyzed radiolabeled OLIG2 proteins by immunoprecipitation (IP) with anti-Myc followed by polyacrylamide gel electrophoresis (PAGE). Two major radioactive OLIG2 bands were visible ( Figure 1A ). Separation of Olig2-transfected Cos-7 cell lysates by two-dimensional (2D) PAGE (pH gradient in the second dimension) followed by Western blotting (WB) confirmed that OLIG2 was phosphorylated on multiple sites and that most of the phosphates could be removed by calf intestinal alkaline phosphatase (CIAP) ( Figures  1C and 1F ). Bioinformatic analysis of OLIG2 using online services NetPhos 2.0 Server (Blom et al., 1999) and NetPhosK 1.0 Server (Blom et al., 2004) identified one potential PKA and one potential protein kinase C (PKC) phosphorylation site (Table S1 ). Alignment of OLIG2 protein sequences from different species revealed that the predicted PKA site (R[R/K]X[S/T]) (X, any amino acid)-at S147 in the bHLH Helix-2 (H2) domain-is conserved during evolution ( Figure 1B ). This site is also conserved in OLIG1 but not in NGN1-3 or other bHLH proteins examined. We mutated S147 to Alanine (S147A), transfected the mutant (Olig2 S147A ) and wild-type (Olig2 WT ) constructs into Cos-7 cells, and visualized OLIG2 proteins by 2D PAGE and WB as before. This revealed an altered phosphorylation pattern of OLIG2 S147A ( Figure 1D ), Figure S2 .
indicating that S147 is a bone fide phosphate acceptor. Moreover, cotransfection of Olig2 WT with a plasmid encoding a dominant-negative form of PKA (dnPKA) strongly reduced the phosphoprotein signal in the low pH range of the 2D gel (the region affected by S147A mutation), implying that OLIG2 can be phosphorylated by PKA on several sites, including S147 ( Figure 1E ).
OLIG2-S147 Is Phosphorylated In Vivo during MN Development
To examine OLIG2-S147 phosphorylation status directly, we raised an antiserum in rabbits against a custom phosphopeptide and purified an antibody fraction that specifically recognizes the S147-phosphorylated form of OLIG2 (anti-OLIG2 ph-S147
; Figure S1 ). We prepared nuclear extracts of embryonic day 9.5 (E9.5), E11.5, and E13.5 mouse spinal cord tissue, immunoprecipitated endogenous OLIG2 protein with a goat anti-OLIG2 antibody, and visualized the precipitates by PAGE and WB with either rabbit anti-OLIG2 or rabbit anti-OLIG2 ph-S147
. OLIG2 was expressed more or less equally at all stages examined ( Figure 1G ). The specific phosphorylated form OLIG2 ph-S147 was present at E9.5 and to a lesser extent at E11.5 ($3.2-fold decrease; see Experimental Procedures) but was not detected at E13.5 ( Figure 1H ). These results demonstrate that endogenous OLIG2 is phosphorylated on S147 during MN production ($E9-12) but is later dephosphorylated, coinciding with the switch from MN to OLP production that occurs around E12.5 in mice (Pringle et al., 1996; Richardson et al., 2006) .
Mutation of S147 to Alanine Changes the Protein Binding Properties of OLIG2 Given the location of the S147 phosphorylation site in the bHLH domain, it seemed likely that the phosphorylation status of this site might affect the interactions of OLIG2 with other proteins or with DNA. OLIG2 can form strong homodimers with itself as well as heterodimers with OLIG1 but forms weak heterodimers with other bHLH proteins, such as E12 or NGN2 (Lee et al., 2005; Li et al., 2007) . It also interacts physically with other nonbHLH transcription factors, including SOX10, NKX2.2, and ZFP488 (Li et al., 2007; Sun et al., 2003; Wang et al., 2006; Wissmuller et al., 2006) . We compared the cofactor-binding properties of OLIG2 S147A and OLIG2
WT by coIP assays in transfected Cos-7 cells and found that, compared to OLIG2 WT , OLIG2 S147A had a reduced ability to form OLIG2-OLIG2 and OLIG2-OLIG1 dimers, whereas binding to NKX2.2, SOX10, or MASH1 was unaffected (Figures 2A and S2A ). In contrast, OLIG2 S147A complexed more readily with NGN2 (Figure 2A) . Together, these experiments indicate that S147A mutation does not destabilize OLIG2 or grossly affect its structure but, nevertheless, alters its binding to transcriptional partners. We tried to mimic constitutive phosphorylation by mutating S147 to glutamic acid (E) or aspartic acid (D). However, both OLIG2 S147E and OLIG2 S147D exhibited reduced homodimer formation just like OLIG2 S147A (data not shown). This sort of effect is not unique to OLIG2. For example, phosphorylation/dephosphorylation of serine/threonine residues of the bHLH transcription factor HAND1 have been shown to regulate homodimer versus heterodimer formation, phosphorylation favoring heterodimers of HAND1 and E proteins and dephosphorylation favoring HAND1 homodimers (Firulli et al., 2003) . However, mutation of the key serine/threonine phosphate acceptors to aspartic acid did not inhibit HAND1 homodimer formation, as would have been expected if these substitutions had mimicked constitutive phosphorylation, but instead strengthened homodimer formation just like serine/threonine / alanine substitution (Firulli et al., 2003) .
We also compared the binding properties of OLIG2 WT and OLIG2 S147A using a mammalian two-hybrid system (CheckMate System, Promega) ( Figures 2B-2E ). This is a bipartite assay that depends on the physical association of test and target proteins at the promoter of a Luciferase reporter gene in Cos-7 cells, so activating Luciferase expression, which can be quantified by chemiluminescence. This assay confirmed the results of co-IP, namely, that association of OLIG2 WT with an OLIG2 S147A target was strongly reduced relative to either an OLIG2 WT or OLIG1 target (Figures 2B and 2C) . In contrast, and also in agreement with the co-IP data, association of NGN2 with OLIG2 S147A was enhanced ( Figure 2D ).
Furthermore, cotransfection of the catalytic subunit of PKA enhanced formation of OLIG2-OLIG2 and OLIG2-OLIG1 dimers while inhibiting OLIG2-NGN2 dimer formation, whereas a dnPKA had the opposite effect ( Figures 2B-2E ). In summary, phosphorylation of OLIG2 on S147, possibly by PKA, has a dramatic effect on cofactor choice, favoring NGN2 over other potential partners. In addition we assessed the DNA binding activities of OLIG2 WT and OLIG2 S147A by electrophoretic mobility shift assay (EMSA).
OLIG2 S147A exhibited significantly weaker binding to the HB9/ M100 E box (Lee et al., 2005) compared to OLIG2 WT ( Figure S2B ).
Given that dimerization is needed for bHLH proteins to bind to DNA targets (Murre et al., 1989) , this result most likely reflects the reduced efficiency of OLIG2 homodimer formation as a result of S147A mutation.
OLIG2
S147A Mutant Mice
In order to study the phenotypic consequences of OLIG2-S147 phosphorylation in vivo, we generated Olig2 S147A mutant mice.
We modified OLIG2-coding sequence in an Olig2 PAC clone (not containing Olig1), introducing the S147A mutation while simultaneously adding a V5 epitope tag to the C terminus (Figure 3A) . Transgenic mice were generated by pronuclear injection. V5-tagged Olig2 S147A and Olig2 WT mice were made in parallel and single-copy founders of both lines were selected for further study ( Figure 3B ). Immunofluorescence microscopy confirmed that the Olig2 S147A and Olig2 WT PAC transgenes were faithfully expressed in the embryonic spinal cords of both lines ( Figures  3C and 3D ). We subsequently removed the endogenous Olig2 alleles by crossing the PAC transgenes into an Olig2 null background , thereby obtaining single-copy Olig2
S147A
and Olig2 WT lines (i.e., Olig2 S147A :Olig2 À/À and Olig2 WT :Olig2 À/À ).
For some experiments we also bred the PAC transgenics with Olig1/Olig2 double-null mice (Zhou and Anderson, 2002) , which express green fluorescent protein (GFP) under transcriptional control of Olig2 (see below).
Olig2 S147A Mice Lack the pMN Precursor Domain in the Ventral VZ Progenitors in p3, the ventral-most progenitor domain of the embryonic spinal cord, express the transcription factor NKX2.2, whereas progenitors in the p2 domain express IRX3 and a high level of PAX6 (Briscoe et al., 2000) . The pMN domain lies between p3 and p2 and is marked by expression of OLIG2 and a low level of PAX6 (Lu et al., 2000; Zhou et al., 2000;  Figure 4A ). OLIG2 is essential for establishing and maintaining the pMN domain through cross-regulatory interactions with transcription factors in neighboring domains. For example, OLIG2 represses expression of Irx3 and Pax6 ; in the absence of OLIG2 function, Irx3 and Pax6 are derepressed in pMN, which takes on the character of p2, generating V2 interneurons and astrocytes instead of MNs and OLPs Zhou and Anderson, 2002) (Figure 4B ). This can be regarded as a ''homeotic'' transformation pMN / p2. We found that the pMN domain specifically was missing in our Olig2 S147A mice ( Figures 4C and 4D ). Moreover, in Olig2 S147A :Olig2 GFP/À , Olig1 +/À embryos, most pMN precursors (marked by GFP) were observed to adopt a p2 fate (high PAX6 expression) ( Figure S3 ). These findings demonstrate that mutation of the S147 phosphate acceptor site destroys the neuroepithelial ''patterning'' function of OLIG2. 2002; Figure 4E ). Similarly, our Olig2 S147A mutant mice failed to generate MNs, judging by the lack of expression of the MN-specific HD transcription factor HB9 ( Figure 4G ). HB9-positive MNs developed normally in Olig2 WT mice ( Figure 4F ). It has been shown previously that forcing ectopic expression of Olig2 in chick neural tube by electroporation at HamiltonHamburger (HH) stage12-14 can induce ectopic production of HB9-positive MNs by 48 hr post-electroporation, mainly in the p2 domain (Novitch et al., 2001; Mizuguchi et al., 2001; Lee et al., 2005) . We confirmed this ability of Olig2 WT to induce ectopic MNs (Figures 4H-4J) but found that Olig2 S147A was inactive in this regard ( Figures 4K-4M ). Taken together, the data strongly suggest that S147 phosphorylation is necessary for the MN-inducing function of OLIG2.
S147 Phosphorylation Is Dispensable for the OL-Inducing Activity of OLIG2
In the spinal cords of Olig2 null mice, expression of the OLP markers PDGFRa and SOX10 is completely absent Takebayashi et al., 2002; Zhou and Anderson, 2002) , demonstrating an essential role for OLIG2 in OL lineage specification. In our Olig2 S147A mutant mice, SOX10-and PDGFRaexpressing OLPs were missing at E14.5 ( Figures 5A-5D ) but appeared later at E18.5, though in reduced numbers ($15%) relative to Olig2 WT controls (Figures 5E, 5F, 5H, and 5I). At the time of their first appearance, OLPs were scattered through all regions of the cord, not concentrated in the ventral cord as in wild-type mice. This is consistent with the demonstrated loss of the ventral pMN domain (Figure 4 )-the source of most but not all OLPs in the cord-and suggests that S147 phosphorylation is not required for OLP specification from other progenitor domains that do not rely on the prior neuroepithelial patterning function of OLIG2. We further investigated the effect of S147 phosphorylation on OLP differentiation into myelin-forming OLs by culturing primary E18.5 spinal cord cells under conditions permissive for OL differentiation. (It was not possible to study OL differentiation in vivo since Olig2 S147A mutants die at birth due to the lack of MNs.) Myelin basic protein (MBP)-positive OLs formed in these mutant cell cultures as in wild-type cultures, demonstrating that S147 phosphorylation is not absolutely required for OL lineage progression ( Figure S4 ).
To examine OLP-inducing activity further, we electroporated Olig2 WT or Olig2 S147A expression vectors into chick neural tube. It has been reported that Olig2 WT can induce expression of OLP markers in the dorsal neural tube, after a delay of around 4 days post-electroporation (Liu et al., 2007) . We found that forced expression of Olig2 S147A induced dorsal SOX10 expression well ahead of this schedule at 48 hr post-electroporation ( Figures 5M and 5N ). As expected, Olig2 WT did not induce SOX10 on this time scale (Figures 5K and 5L) . Taken together, our data suggest that OL fate is favored, even accelerated, when OLIG2 is not phosphorylated on S147.
OLIG2 S147A Favors OL Lineage Development in Cultured P19 Cells To investigate further the role of OLIG2-S147 phosphorylation in neural fate determination, we turned to an in vitro assay using P19 cells. This pluripotent embryonal carcinoma (EC)-derived cell line can differentiate into different cell lineages under appropriate inductive conditions (Jones-Villeneuve et al., 1982 , 1983 . For example, cell aggregation together with retinoic acid (RA) treatment drives the differentiation of P19 cells toward a neural fate, even as early as 4 hr postinduction (Berg and McBurney, 1990; Staines et al., 1996) . We treated aggregated P19 cells with RA together with the SHH small-molecule agonist SHHAg1.2, a combination that can initiate MN development in cultured embryonic stem (ES) cells (Wichterle et al., 2002) . We found that RA/SHHAg1.2 also induced the MN marker HB9 in aggregated P19 cells ( Figures 6A and 6B) . Furthermore, this treatment induced expression of proteoglycan NG2, which marks OLPs ( Figures 6E and 6F) .
To study the influence of OLIG2 on neural differentiation of P19 cells, we constructed two stable P19 lines that constitutively expressed V5-tagged OLIG2 Figures 6C and 6G ). This is in keeping with previous reports that constitutive expression of OLIG2 WT can enhance the output of MNs and OL lineage cells from ES cells (Du et al., 2006; Shin et al., 2007) . Under inducing conditions P19-OLIG2 S147A cultures developed a decreased number of HB9-positive cells (p < 0.05) compared with control P19 cells ( Figure 6D ), demonstrating a dominantnegative effect of the S147A mutant protein over endogenous, wild-type OLIG2 (which is also present in the P19 lines). Strikingly, P19-OLIG2 S147A cells induced with RA/SHHAg1.2 generated many more NG2-positive cells compared to induced P19-OLIG2 WT (p < 0.001) or parental P19 (p < 0.001) lines ( Figures  6F-6J ). The induced NG2-positive cells also expressed SOX10 ( Figure 6I ) and MBP ( Figure S5 ). These data provide strong confirmation that loss of OLIG2-S147 phosphorylation directs NSCs away from an MN fate toward the OL lineage.
DISCUSSION
We have shown that phosphorylation of OLIG2 on S147 is required for the early functions of OLIG2 in neuroepithelial patterning and MN specification but is subsequently dispensable for OLP specification. We have also shown that S147 is phosphorylated during MN specification in the ventral spinal cord, dephosphorylated at the onset of OLP production, and that that dephosphorylation switches the binding preference of OLIG2 away from OLIG1/2 toward NGN2. We believe that this represents a key part of the regulatory mechanism that operates through OLIG2 to switch NSC fate from MNs to OLPs during ventral spinal cord development. Other phosphorylation events might also be important for the functional regulation of OLIG2, e.g., it was recently shown that casein kinase 2 (CK2)-mediated phosphorylation is required for the oligodendrogenic activity of OLIG2 (Huillard et al., 2010) . Serine phosphorylation of NGN2 by glycogen synthase kinase-3 (GSK3) has also been shown to promote MN specification by facilitating assembly of NGN2 into a transcriptional complex with homeodomain factors LHX3 and ISL1/2 (Ma et al., 2008) . It seems that phosphorylation of bHLH proteins (and perhaps other posttranslational modifications) might be a common means of regulating cell fate and lineage progression.
OLIG2-S147 Phosphorylation and the MN-OL Fate Switch
Our data reveal that gain or loss of a phosphate group on OLIG2-S147 goes hand in hand with MN or OL generation, respectively. mice, and these were delayed, appearing at E15.5-17.5 instead of E12.5 as in wildtype cord. This fits with the fact that the pMN progenitor domain, which normally produces $80% of all OLPs in the cord, is lost in the mutant. The remaining $20% of OLPs are produced from more dorsal progenitor domains, which do not depend on the neuroepithelial patterning function of OLIG2 (Cai et al., 2005; Fogarty et al., 2005; Vallstedt et al., 2005) . These dorsally derived OLPs are generated later than pMN-derived OLPs ($E16.5 versus E12.5). They still require OLIG2 function for their development, for in Olig2 À/À mice there are no spinal OLPs whatsoever Takebayashi et al., 2002 We found that OLIG2 S147A has an enhanced ability to bind NGN2, coupled with a diminished ability to form dimers with itself or OLIG1. Consistent with this, we found that OLIG2 S147A inhibits NGN2-mediated transcriptional activation of the HB9 promoter more efficiently than does OLIG2
WT , in cotransfection assays with an HB9:luciferase reporter ( Figure S6 ). NGN2 is a bHLH transcription factor that is known to be required for MN development because spinal MNs are not formed properly in mice lacking NGN2 (Scardigli et al., 2001 ). OLIG2 and NGN2 are coexpressed in the pMN domain and nowhere else, implying that OLIG2 and NGN2 act in concert during MN development (Mizuguchi et al., 2001; Novitch et al., 2001 ). There is evidence that OLIG2/NGN2 coexpression drives NSCs to exit the cell cycle and start expressing pan-neuronal markers (Mizuguchi et al., 2001; Novitch et al., 2001; Lee et al., 2005) . NGN2 expression is later downregulated in pMN, and this was suggested to be necessary to enable pMN progenitors to switch from MN to OLP production (Zhou et al., 2001) . However, in the light of our current data, we believe that NGN2 downregulation is not the trigger but rather a consequence of the MN-OLP switch that reinforces and stabilizes the gliogenic state. Taken together with previous research, our data provide new ideas about the chain of events leading up to and beyond the MN-OLP fate switch. We propose that during the early neurogenic phase ($E9-E12), homodimers of S147-phosphorylated OLIG2 act to repress OL lineage genes in pMN and create a permissive environment for MN development-in which NGN2 plays an important role in concert with homeodomain transcription factors ISL1/2 and LHX3 (Lee and Pfaff, 2003; Lee et al., 2005; Ma et al., 2008) . Subsequently, dephosphorylation of OLIG2-S147 disrupts OLIG2 homodimers and encourages formation of heterodimers such as OLIG2/NGN2, thereby sequestering NGN2 and possibly other bHLH factors and shutting down MN lineage genes. At the same time, OLIG2 associates with other unidentified cofactors to activate the OL genetic program and repress the MN program (including NGN2), hence reinforcing the neuron-glial switch. This scheme is illustrated in Figure 7 . However, we note that endogenous MN development did not appear to be inhibited in OLIG2 S147A :OLIG2 +/À mice (data not shown) or in OLIG2 S147A -electroporated chick (Figure 4L ), which could be taken to argue against the simple sequestration model depicted. However, it is possible that in both these situations OLIG2 S147A expression might not have been robust enough to completely overcome endogenous OLIG2 function. A potential partner of OLIG2 that might come into play during OL lineage specification is NKX2.2. Forced expression of OLIG2 together with NKX2.2 in chick neural tube induces early onset of OLP specification (Sun et al., 2001 ). In addition, OLIG2 and NKX2.2 can physically interact with each other (Sun et al., 2003) . However, OLIG2 and NKX2.2 are not tightly colocalized in the pMN domain in the run up to MN-OLP fate switching in mice (Sun et al., 1998; Richardson et al., 2006) , so it is not clear that OLIG2 and NKX2.2 normally work together in OLP specification. In fact, OLPs develop normally in NKX2.2 null mice, although their subsequent differentiation into OLs is prevented (Qi et al., 2001) . Another potential cofactor for OLIG2 is MASH1/ASCL1; initially ($E12.5) there are reduced numbers of OLPs in MASH1 null spinal cords, but this soon resolves, suggesting that MASH1 is not critical for OLP specification (Sugimori et al., 2008) . We found that S147A mutation did not have a noticeable effect on binding of OLIG2 to either NKX2.2 or MASH1 (Figure S2A) , so we probably have to look elsewhere for critical determinants of OL lineage specification in the spinal cord. The transcription factor NF1A has been proposed to trigger gliogenesis throughout the neural tube (Deneen et al., 2006) , but its physical and functional relationships with OLIG2 have yet to be investigated. Recently, OLIG2 was shown to interact with the bHLH protein E47 to directly activate the Sox10-U2 promoter in the OL lineage (Kü spert et al., 2010) . The results of our present study suggest that dephosphorylated OLIG2 S147 might specifically interact with E47 in this context. Epigenetic modifications play an important part in cell fate decisions, including OLP specification. For example, in the A key feature is that dephosphorylation of OLIG2 increases the efficiency of OLIG2-NGN2 heterodimer formation, reducing the amount of NGN2 available for activating MN-specific genes and thereby contributing to the neuron-OL fate switch.
absence of histone deacetylases 1 and/or 2 (HDAC1/2), OLP formation in the ventral spinal cord is disrupted (Cunliffe and Casaccia-Bonnefil, 2006; Ye et al., 2009; Li et al., 2009 ). It will be important in the future to investigate the potential interactions between OLIG2, HDACs, and other histone modifiers (e.g., methylases) and how these interactions might be influenced by posttranslational modification.
The Role of PKA Our study focused on reversible phosphorylation of OLIG2-S147, an evolutionarily conserved site that is predicted to be a PKA target. We provided evidence that OLIG2-S147 can be phosphorylated by PKA in cultured Cos-7 cells and that dnPKA inhibits phosphorylation. Despite this, we cannot conclude that PKA is the only-or even the primary-protein serine kinase to target S147 in vivo. For example, the consensus target sequence for
. Indeed, PKA and PKC are thought to phosphorylate common acceptor sites on the bHLH proteins HAND1 and HAND2 (Firulli et al., 2003) .
Nevertheless, the fact that Olig2 S147A mice failed to develop
MNs suggests that PKA might normally play a positive role in MN development. This seems counter to the popular idea that PKA negatively regulates the SHH pathway (Li et al., 1995; Ruiz i Altaba, 1999; Epstein et al., 1996; Hammerschmidt et al., 1996; Jacob and Briscoe, 2003) . SHH signaling works through the transcription factors GLI1-3, vertebrate homologs of Drosophila Cubitus interruptus (Ci). SHH activates GLI3 (and GLI2) by inducing its proteolytic conversion from a full-length transcriptional activator into a truncated N-terminal repressor (Ruppert et al., 1990; Dai et al., 1999; Wang et al., 2000) . It is believed that PKA phosphorylation stimulates GLI3 cleavage Tempe et al., 2006) , which might underlie the repressive action of PKA on SHH signaling since truncated GLI3 represses the SHH pathway (Dai et al., 1999; Wang et al., 2000; Bai et al., 2004; Tempe et al., 2006) . GLI3 is not the only component of the SHH pathway that can be PKA phosphorylated, and PKA has been shown to play a positive as well as a negative role in SHH signaling. For example, in Drosophila, PKA phosphorylation of SMO, the Hedgehog (HH) coreceptor, promotes SMO accumulation on the primary cilium and triggers HH pathway activation (Jia et al., 2004) . Also, during limb development, elevating PKA activity by Forskolin treatment or by infecting with a retroviral PKA expression vector exerts a positive effect on SHH signaling, resulting in an altered pattern of digits (Tiecke et al., 2007) . We examined the effect of stimulating the PKA pathway in neonatal mouse cortical cell cultures with Forskolin and dibutyryl cyclic AMP (db-cAMP), a cell-permeable analog of cAMP, and found that the number of NG2-positive OLPs was significantly decreased compared to untreated cultures (Figure S7) . This is consistent with expectation since our other data predict that elevating PKA activity should increase OLIG2-S147 phosphorylation and stimulate neurogenesis at the expense of OLPs. However, in the light of the above discussion, it is clear that PKA probably has multiple parallel functions, and our experiments with Forskolin/db-cAMP should be interpreted cautiously.
What Signals S147 Dephosphorylation? Our data raise the obvious question: What is the key event that signals S147 dephosphorylation and triggers the MN-OLP switch in pMN? Notch signaling is known to play an important role in glial cell development in the CNS (Wang et al., 1998; Park and Appel, 2003; Park et al., 2005; Deneen et al., 2006) . Constitutive activation of components of the Notch pathway in chick spinal cord can downregulate NGN2 expression in pMN and initiate OLP generation (Zhou et al., 2001) . Notch1 is expressed by neuroepithelial cells throughout the neural tube, and its ligand Jagged-2 is expressed exclusively in the pMN domain of zebrafish spinal cord during late neurogenesis (Yeo and Chitnis, 2007) . These and other observations frame the Notch pathway as a potential key player in the MN-OLP switch. It is possible that activated Notch-1, via its effector HES5, might induce expression of specific phosphatases and/or repress phosphatase inhibitors, resulting in dephosphorylation of OLIG2-S147 and initiation of OLP production. It will be worth exploring these ideas in the future. By improving our understanding of OL lineage specification, this work might aid the design of procedures for efficient large-scale production of OL lineage cells for clinical use-cell replacement therapy for demyelinating diseases like multiple sclerosis, for example-or for high-throughput drug screens. Study of the posttranslational pathways that modulate transcriptional activity of OLIG2, NGN2 and other related factors might also provide insights into general mechanisms of stem cell fate choice.
EXPERIMENTAL PROCEDURES
Plasmid Vectors
Open reading frames of mouse Olig1, Olig2, Sox10, Ngn2, Mash1, and Nkx2.2 were amplified by RT-PCR from RNA extracted from mouse embryonic spinal cord tissue and subcloned into Invitrogen's pCDNA3.1-V5 and/or pCDNA4-myc vectors, or Promega's pBIND and/or pACT vectors (for two-hybrid assays). Catalytic PKA and dnPKA vectors were kindly provided by Dr. Judy Varner (University of California, San Diego). S147A mutant vectors were generated using Stratagene's QuikChange Site-Directed Mutagenesis Kit following the manufacturer's instructions. The HB9-luciferase reporter plasmid HB9:luc (Lee et al., 2005 ) was a gift from Dr. Samuel Pfaff (Salk Institute, La Jolla, CA, USA).
Antibodies and In Situ Hybridization Probes
Primary antibodies used for WB and IP were as follows: goat anti-OLIG2 (R&D Systems; used at 1:250 dilution for IP); rabbit anti-OLIG2 (a gift from Charles Stiles, Dana Farber Cancer Institute; 1:20,000 for WB); mouse anti-Myc (Sigma; 1:5,000 for WB); rabbit anti-Myc (Abcam; 1:500 for IP); and mouse anti-V5 (Abcam; 1:2,500 for WB). The specific anti-OLIG2 ph-S147 antibody was generated by CovalAb UK, Cambridge. The sequence of the immunizing peptide was YAHGPSVRKL-(phospho-S147)-KIA (residues 137-150 of OLIG2). Rabbits were immunized four times with peptide, and antiserum was collected 25 days after the last injection. The antiserum was first absorbed on a column containing nonphosphorylated peptide and then affinity purified on a phosphopeptide column. The purified antibody was used in WB at a dilu LGC-ATCC and maintained in Alpha minimal essential medium with ribonucleosides and deoxyribonucleosides, supplemented with 5% fetal bovine serum (Invitrogen) at 37 C with 5% CO 2 . For differentiation assays, 5 3 10 4 P19 cells were plated on 35 mm diameter plates in medium with 1% serum. After 5-6 days, the aggregated cells were treated with 1 mM RA and 100 nM SHHAg1.2 (Curis, Inc.). Cells were fixed for immunolabeling after two more days in culture.
IP and WBs
Cultured cells were lysed by homogenization in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate, and one tablet of protease inhibitor mix per 50 ml buffer. Lysis buffer for spinal cord tissue was purchased from Sigma (CelLytic MT); sometimes phosphatase inhibitors were included. After lysis, cell debris was removed by centrifugation at 30,000 3 g, then 500 ml cell lysate was treated with 50 U of DNase1 and precleared with 30 ml of protein G beads (GE Healthcare) for 3 hr at 4 C on a rotating wheel. The supernatant was decanted, incubated with the antibody of interest at 4 C for 1 hr, mixed with 30 ml of protein G beads, and incubated overnight at 4 C. The beads were washed twice in lysis buffer, twice in highsalt buffer (50 mM Tris-HCl [pH 7.5], 500 mM NaCl, 0.1% [v/v] Nonidet P-40, 0.05% [w/v] sodium deoxycholate) and once in low-salt buffer (50 mM TrisHCl [pH 7.5], 0.1% Nonidet P-40, 0.05% sodium deoxycholate). The beads were resuspended in 30 ml of SDS gel sample buffer, boiled for 5 min, and subjected to SDS-PAGE followed by WB. Band intensity was quantified using ImageJ software. For 2D PAGE the beads were treated with Invitrogen ZOOM Protein Solubilizer, and protein samples were separated on the Invitrogen ZOOM 2D gel system following the manufacturer's instructions. After electrophoresis, proteins were transferred to polyvinylidene difluoride membranes. Protein bands were visualized by chemiluminescence (ECLplus kit; GE Healthcare).
In Vitro Phosphorylation Assays Thirty-six hours after transfection, Cos-7 cells were washed twice with phosphate-free DMEM (Invitrogen). Thirty mega-becquerels [ 33 P]orthophosphate (Amersham) were added to phosphate-free medium, and cells incubated for 4 hr at 37 C. The medium was then removed, and the cells washed twice with ice-cold PBS and immediately lysed on ice (see above). Proteins were immunoprecipitated, separated by SDS-PAGE, and visualized by autoradiography.
Two-Hybrid Protein Binding Assays
Two-hybrid assays for protein-protein interactions were performed using Dual Luciferase Assay System (Promega). The amounts of transfected DNAs were normalized with empty pCDNA vector. The measured firefly luciferase activity was normalized against Renilla Luciferase activity. Three independent transfections were conducted in parallel for each condition, and each experiment was repeated three times.
In Ovo Electroporation of Chick Embryos
Fertilized chicken eggs were supplied by Henry Stuart Inc. and incubated at 38 C in a humidified atmosphere. The embryos were staged according to HH and electroporated at HH12-14 (Hamburger and Hamilton, 1992) . Expression constructs were diluted in injection buffer (3 mg/ml in PBS containing 0.8% [w/v] Fast Green), injected into the spinal cord lumen, and electroporated using an Intracel TSS20 Ovodyne electroporator with EP21 current amplifier. Embryos were analyzed 48 hr later. 
Immunohistochemistry and In Situ Hybridization
ACKNOWLEDGMENTS
We thank our colleagues in the Wolfson Institute for Biomedical Research, particularly Marta del Barrio and Raquel Taveira-Marques, for helpful advice and discussions. We gratefully acknowledge Nicoletta Kessaris for help with triple-label immunofluorescence ( Figure 4A ) and Richa Tripathi for confocal micrography ( Figure 5 
